search
Back to results

Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

Primary Purpose

Breast Neoplasms

Status
Terminated
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
CP-751,871
exemestane
exemestane
Fulvestrant
Sponsored by
Pfizer
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Breast Neoplasms

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Postmenopausal women with a diagnosis of hormone receptor positive advanced breast cancer
  • HbA1c <5.7%

Exclusion Criteria:

  • Previous treatment for advanced disease

Sites / Locations

  • UCSD Medical Center - La Jolla
  • UCSD Moores Cancer Center
  • UCSD Medical Center - Hillcrest
  • Washington Cancer Institute (WCI) at Washington Hospital Center (WHC)
  • Florida Cancer Research Institute
  • Florida Cancer Research Institute
  • Central Baptist Hospital
  • Lexington Oncology Associates
  • Bluegrass Hematology/Oncology, PSC
  • Massachusetts General Hospital
  • Bringham and Women's Hospital
  • Dana-Farber Cancer Institute
  • Beth Israel Deaconess Medical Center
  • Dana-Farber Cancer Institute (DFCI)
  • Dana-Farber Cancer Institute
  • University of Minnesota Medical Center-Fairview, Riverside Campus
  • University of Minnesota Cancer Center
  • University Of Minnesota Medical Center
  • Alamance Regional Medical Center - Cancer Center
  • Duke University Medical Center - Morris Cancer Center Clinics
  • Duke University Medical Center- Department of Medicine Oncology
  • Duke University Medical Center-Duke Cancer Center
  • Duke University Medical Center
  • Duke University School Of Medicine
  • Texas Oncology - PA Collins Building 5th Floor
  • Baylor College Of Medicine (Bcm)
  • Baylor College of Medicine Breast Center
  • Fletcher Allen Healthcare
  • Fletcher Allen Health Care
  • Fletcher Allen Hospital MCHV Campus
  • Pharmacist, Investigational Drug Service
  • Fletcher Allen Healthcare
  • Fletcher Allan Health Care
  • Policlinica Privada Site La Plata S.A.
  • Breast Clinica de la Mama
  • Policlinica Privada Site
  • Policlinica Privada Site La Plata S. A.
  • Instituto de Investigaciones Clinicas
  • Centro Oncologico Rosario
  • Centro Oncologico De Rosario
  • Centro Oncologico
  • Hospital Italiano Cordoba
  • UZ Gasthuisberg, Medische Oncologie
  • UZ Gasthuisberg
  • Oncologisch Centrum GZA
  • Jewish General Hospital
  • Instituto Nacional de Cancer - HCII
  • Hospital Sao Lucas da PUCRS
  • Instituto Nacional DO Cancer - INCA
  • Clínica de Oncologia de porto Alegre Sociedade Simples ltda.
  • Hospital Sao Lucas da PUCRS
  • Hospital Das Clinicas Da Faculdade De Medicina Da Universidade De Sao Paulo Instituto Central
  • Centro de Pesquisa em Oncologia - CPO
  • Instituto Nacional do Cancer
  • Cross Cancer Institute
  • Sir Mortimer B. Davis - Jewish General Hospital
  • Dipartimento di Medicina, Divisione di Oncologia Medica, Istituto Europeo di Oncologia
  • Divisione di Oncologia
  • Uo Oncologia Medica 2 Regione Del Veneto Istituto Oncologico Veneto IRCCS Ospedale Busonera
  • VU University Medical Center
  • Malmö University Hospital
  • St Mary's Hospital NHS Trust
  • Imperial College Healthcare NHS Trust - Charing Cross Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

1

2

Arm Description

CP-751,871 + exemestane Treatment until progression or toxicity

Outcomes

Primary Outcome Measures

Progression-Free Survival (PFS)
PFS was calculated from the time of randomization to either progression of disease, death, or treatment discontinuation because of unsatisfactory therapy results (such as global deterioration of health status). Disease progression was defined as 1 or more of the following: radiographic progression (20 percent [%] increase in measurable lesions, appearance of new lesions or unequivocal progression of evaluable lesions as defined by Response Evaluation Criteria in Solid Tumors [RECIST]); occurrence of new pleural/pericardial effusions or ascites confirmed by positive cytology; persistent hypercalcemia requiring more than 2 IV treatments with bisphosphonates; intervention for any cancer-related events (radiations, surgery) or new symptoms related to tumor growth requiring participant discontinuation; development of brain metastasis; or death for any cause. Median PFS was estimated from the Kaplan-Meier curve. 95% confidence interval (CI) is based on the Brookmeyer and Crowley method.
PFS in Participants With Hemoglobin A1c (HbA1c) Less Than (<) 5.7% at Baseline
PFS was calculated from the time of randomization to either progression of disease, death, or treatment discontinuation because of unsatisfactory therapy results (such as global deterioration of health status). Disease progression was defined as 1 or more of the following: radiographic progression (20% increase in measurable lesions, appearance of new lesions or unequivocal progression of evaluable lesions as defined by RECIST); occurrence of new pleural/pericardial effusions or ascites confirmed by positive cytology; persistent hypercalcemia requiring more than 2 IV treatments with bisphosphonates; intervention for any cancer-related events (radiations, surgery) or new symptoms related to tumor growth requiring participant discontinuation; development of brain metastasis; or death for any cause. Median PFS was estimated from the Kaplan-Meier curve. 95% CI is based on the Brookmeyer and Crowley method.

Secondary Outcome Measures

Percentage of Participants Achieving Complete Response (CR), Partial Response (PR), or Stable Disease (SD) Maintained for at Least 6 Months
Objective responses were defined using RECIST as CR: disappearance of all target and nontarget lesions. PR: at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as a reference the baseline sum LD. Nontarget lesions may persist provided there is no unequivocal progression in these lesions. SD: measurements demonstrating neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify as progressive disease (PD) during the first 6 weeks after the start of treatment taking as reference the smallest sum LD since the treatment started. During this time, nontarget lesions may persist provided there is no unequivocal progression in these lesions.
Maximum Plasma Concentration of CP-751,871
Minimum Plasma Concentration of CP-751,871
Area Under the Concentration Time Curve From Time 0 to the Last Time Point With Quantifiable Concentration
Number of Participants With Negative Human Anti-Human Antibodies (HAHAs)
Negative human anti-human antibodies were defined as <6.64
Percentage of Participants With Circulating Tumor Cells Expressing Insulin-Like Growth Factor 1 Receptor (IGF-IR)
Percentage of Participants With Serum Markers Relevant to the IGF-1R Pathway
European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire 30 (QLQ-C30) Scores
EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score equals (=) better level of functioning or greater degree of symptoms.
EORTC QLQ Breast Cancer Module (BR23) Scores
EORTC-QLQ-BR23: included functional scales (body image, sexual functioning, sexual enjoyment, and future perspective) and single item symptoms scales (systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss). Questions used 4-point Likert scale (1 ‘Not at All’ to 4 ‘Very Much’). Scores averaged and transformed to 0-100 scale. High score for functional scale=high/healthy level of functioning. High score for single item=high level of symptomatology/problems. Change from baseline=Cycle/Day score minus baseline score.

Full Information

First Posted
September 5, 2006
Last Updated
October 6, 2015
Sponsor
Pfizer
search

1. Study Identification

Unique Protocol Identification Number
NCT00372996
Brief Title
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
Official Title
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
October 2015
Overall Recruitment Status
Terminated
Why Stopped
This study was closed to enrollment as of 13 May 2011 due to business reasons. Premature closure was not prompted by any safety or efficacy concerns.
Study Start Date
February 2007 (undefined)
Primary Completion Date
September 2012 (Actual)
Study Completion Date
June 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pfizer

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
To test the efficacy of CP-751,871 combined with exemestane in the treatment of postmenopausal patients with hormone positive advanced breast cancer

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Neoplasms

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
219 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
CP-751,871 + exemestane Treatment until progression or toxicity
Arm Title
2
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
CP-751,871
Intervention Description
CP-751,871 given at 20 mg/kg IV on day 1 of each 21 day cycle.
Intervention Type
Drug
Intervention Name(s)
exemestane
Intervention Description
Exemestane given at 25 mg orally once a day.
Intervention Type
Drug
Intervention Name(s)
exemestane
Intervention Description
Exemestane given at 25 mg orally once a day. Treatment until progression or toxicity
Intervention Type
Drug
Intervention Name(s)
Fulvestrant
Intervention Description
Used for salvage therapy and administered according to the local label and standard clinical practice.
Primary Outcome Measure Information:
Title
Progression-Free Survival (PFS)
Description
PFS was calculated from the time of randomization to either progression of disease, death, or treatment discontinuation because of unsatisfactory therapy results (such as global deterioration of health status). Disease progression was defined as 1 or more of the following: radiographic progression (20 percent [%] increase in measurable lesions, appearance of new lesions or unequivocal progression of evaluable lesions as defined by Response Evaluation Criteria in Solid Tumors [RECIST]); occurrence of new pleural/pericardial effusions or ascites confirmed by positive cytology; persistent hypercalcemia requiring more than 2 IV treatments with bisphosphonates; intervention for any cancer-related events (radiations, surgery) or new symptoms related to tumor growth requiring participant discontinuation; development of brain metastasis; or death for any cause. Median PFS was estimated from the Kaplan-Meier curve. 95% confidence interval (CI) is based on the Brookmeyer and Crowley method.
Time Frame
Baseline, Day 1 of Cycles 2 and 4 and then Day 1 of every 3rd cycle starting at Cycle 7 up to 60 months
Title
PFS in Participants With Hemoglobin A1c (HbA1c) Less Than (<) 5.7% at Baseline
Description
PFS was calculated from the time of randomization to either progression of disease, death, or treatment discontinuation because of unsatisfactory therapy results (such as global deterioration of health status). Disease progression was defined as 1 or more of the following: radiographic progression (20% increase in measurable lesions, appearance of new lesions or unequivocal progression of evaluable lesions as defined by RECIST); occurrence of new pleural/pericardial effusions or ascites confirmed by positive cytology; persistent hypercalcemia requiring more than 2 IV treatments with bisphosphonates; intervention for any cancer-related events (radiations, surgery) or new symptoms related to tumor growth requiring participant discontinuation; development of brain metastasis; or death for any cause. Median PFS was estimated from the Kaplan-Meier curve. 95% CI is based on the Brookmeyer and Crowley method.
Time Frame
Baseline, Day 1 of Cycles 2 and 4 and then Day 1 of every 3rd cycle starting at Cycle 7 up to 60 months
Secondary Outcome Measure Information:
Title
Percentage of Participants Achieving Complete Response (CR), Partial Response (PR), or Stable Disease (SD) Maintained for at Least 6 Months
Description
Objective responses were defined using RECIST as CR: disappearance of all target and nontarget lesions. PR: at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as a reference the baseline sum LD. Nontarget lesions may persist provided there is no unequivocal progression in these lesions. SD: measurements demonstrating neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify as progressive disease (PD) during the first 6 weeks after the start of treatment taking as reference the smallest sum LD since the treatment started. During this time, nontarget lesions may persist provided there is no unequivocal progression in these lesions.
Time Frame
Baseline, Day 1 of Cycles 2 and 4 and then Day 1 of every 3rd cycle starting at Cycle 7 up to 60 months
Title
Maximum Plasma Concentration of CP-751,871
Time Frame
Predose on Day 1 at Cycles 1, 2, 4, and 5 and 150 days post last dose of CP-751,871 and for salvage therapy, at Day 1 and 150 days post last dose of CP-751,871
Title
Minimum Plasma Concentration of CP-751,871
Time Frame
Predose on Day 1 at Cycles 1, 2, 4, and 5 and 150 days post last dose of CP-751,871 and for salvage therapy, at Day 1 and 150 days post last dose of CP-751,871
Title
Area Under the Concentration Time Curve From Time 0 to the Last Time Point With Quantifiable Concentration
Time Frame
Predose on Day 1 at Cycles 1, 2, 4, and 5 and 150 days post last dose of CP-751,871 and for salvage therapy, at Day 1 and 150 days post last dose of CP-751,871
Title
Number of Participants With Negative Human Anti-Human Antibodies (HAHAs)
Description
Negative human anti-human antibodies were defined as <6.64
Time Frame
Predose on Day 1 of Cycle 1 and at 150 days post last CP-751,871 infusion
Title
Percentage of Participants With Circulating Tumor Cells Expressing Insulin-Like Growth Factor 1 Receptor (IGF-IR)
Time Frame
Predose on Day 1 of Cycle 1
Title
Percentage of Participants With Serum Markers Relevant to the IGF-1R Pathway
Time Frame
Predose on Day 1 of Cycles 1 and 4 and at end of treatment prior to beginning salvage therapy
Title
European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire 30 (QLQ-C30) Scores
Description
EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score equals (=) better level of functioning or greater degree of symptoms.
Time Frame
Predose on Day 1 of each cycle, at the end of treatment and at follow-up, up to 60 months
Title
EORTC QLQ Breast Cancer Module (BR23) Scores
Description
EORTC-QLQ-BR23: included functional scales (body image, sexual functioning, sexual enjoyment, and future perspective) and single item symptoms scales (systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss). Questions used 4-point Likert scale (1 ‘Not at All’ to 4 ‘Very Much’). Scores averaged and transformed to 0-100 scale. High score for functional scale=high/healthy level of functioning. High score for single item=high level of symptomatology/problems. Change from baseline=Cycle/Day score minus baseline score.
Time Frame
Predose on Day 1, at end of treatment, and at Follow-up, up to 60 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Postmenopausal women with a diagnosis of hormone receptor positive advanced breast cancer HbA1c <5.7% Exclusion Criteria: Previous treatment for advanced disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pfizer CT.gov Call Center
Organizational Affiliation
Pfizer
Official's Role
Study Director
Facility Information:
Facility Name
UCSD Medical Center - La Jolla
City
La Jolla
State/Province
California
ZIP/Postal Code
92037
Country
United States
Facility Name
UCSD Moores Cancer Center
City
La Jolla
State/Province
California
ZIP/Postal Code
92093
Country
United States
Facility Name
UCSD Medical Center - Hillcrest
City
San Diego
State/Province
California
ZIP/Postal Code
92103
Country
United States
Facility Name
Washington Cancer Institute (WCI) at Washington Hospital Center (WHC)
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20010-3017
Country
United States
Facility Name
Florida Cancer Research Institute
City
Davie
State/Province
Florida
ZIP/Postal Code
33328
Country
United States
Facility Name
Florida Cancer Research Institute
City
Plantation
State/Province
Florida
ZIP/Postal Code
33324
Country
United States
Facility Name
Central Baptist Hospital
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40503
Country
United States
Facility Name
Lexington Oncology Associates
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40503
Country
United States
Facility Name
Bluegrass Hematology/Oncology, PSC
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40504
Country
United States
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Facility Name
Bringham and Women's Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Facility Name
Dana-Farber Cancer Institute
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Facility Name
Beth Israel Deaconess Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Facility Name
Dana-Farber Cancer Institute (DFCI)
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Facility Name
Dana-Farber Cancer Institute
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
2215
Country
United States
Facility Name
University of Minnesota Medical Center-Fairview, Riverside Campus
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55454
Country
United States
Facility Name
University of Minnesota Cancer Center
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55455
Country
United States
Facility Name
University Of Minnesota Medical Center
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55455
Country
United States
Facility Name
Alamance Regional Medical Center - Cancer Center
City
Burlington
State/Province
North Carolina
ZIP/Postal Code
27215-8700
Country
United States
Facility Name
Duke University Medical Center - Morris Cancer Center Clinics
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Facility Name
Duke University Medical Center- Department of Medicine Oncology
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Facility Name
Duke University Medical Center-Duke Cancer Center
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Facility Name
Duke University Medical Center
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Facility Name
Duke University School Of Medicine
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Facility Name
Texas Oncology - PA Collins Building 5th Floor
City
Dallas
State/Province
Texas
ZIP/Postal Code
75246-2006
Country
United States
Facility Name
Baylor College Of Medicine (Bcm)
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Baylor College of Medicine Breast Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Fletcher Allen Healthcare
City
Burlington
State/Province
Vermont
ZIP/Postal Code
05401-1473
Country
United States
Facility Name
Fletcher Allen Health Care
City
Burlington
State/Province
Vermont
ZIP/Postal Code
05401
Country
United States
Facility Name
Fletcher Allen Hospital MCHV Campus
City
Burlington
State/Province
Vermont
ZIP/Postal Code
05401
Country
United States
Facility Name
Pharmacist, Investigational Drug Service
City
Burlington
State/Province
Vermont
ZIP/Postal Code
05401
Country
United States
Facility Name
Fletcher Allen Healthcare
City
Burlington
State/Province
Vermont
ZIP/Postal Code
05405
Country
United States
Facility Name
Fletcher Allan Health Care
City
Burlington
State/Province
Vermont
ZIP/Postal Code
5401
Country
United States
Facility Name
Policlinica Privada Site La Plata S.A.
City
La Plata
State/Province
Buenos Aires
ZIP/Postal Code
B1902 CMV
Country
Argentina
Facility Name
Breast Clinica de la Mama
City
La Plata
State/Province
Buenos Aires
ZIP/Postal Code
B1902CMV
Country
Argentina
Facility Name
Policlinica Privada Site
City
La Plata
State/Province
Buenos Aires
ZIP/Postal Code
B1902CMV
Country
Argentina
Facility Name
Policlinica Privada Site La Plata S. A.
City
La Plata
State/Province
Buenos Aires
Country
Argentina
Facility Name
Instituto de Investigaciones Clinicas
City
Rosario
State/Province
Santa Fe
ZIP/Postal Code
S2000CVD
Country
Argentina
Facility Name
Centro Oncologico Rosario
City
Rosario
State/Province
Santa Fe
ZIP/Postal Code
S2000DSK
Country
Argentina
Facility Name
Centro Oncologico De Rosario
City
Rosario
State/Province
Santa Fe
ZIP/Postal Code
S2000KZE
Country
Argentina
Facility Name
Centro Oncologico
City
Rosario
State/Province
Santa Fé
ZIP/Postal Code
S2000KZE
Country
Argentina
Facility Name
Hospital Italiano Cordoba
City
Cordoba
ZIP/Postal Code
X5004BAL
Country
Argentina
Facility Name
UZ Gasthuisberg, Medische Oncologie
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Facility Name
UZ Gasthuisberg
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Facility Name
Oncologisch Centrum GZA
City
Wilrijk
ZIP/Postal Code
2610
Country
Belgium
Facility Name
Jewish General Hospital
City
Montreal
State/Province
QC
ZIP/Postal Code
H3T 1E2
Country
Brazil
Facility Name
Instituto Nacional de Cancer - HCII
City
Santo Cristo
State/Province
Rio de Janeiro
ZIP/Postal Code
RJ 20220-410
Country
Brazil
Facility Name
Hospital Sao Lucas da PUCRS
City
Porto Alegre
State/Province
Rio Grande do Sul
ZIP/Postal Code
90610-000
Country
Brazil
Facility Name
Instituto Nacional DO Cancer - INCA
City
Rio de Janeiro
State/Province
RJ
ZIP/Postal Code
20560-120
Country
Brazil
Facility Name
Clínica de Oncologia de porto Alegre Sociedade Simples ltda.
City
Porto Alegre
State/Province
RS
ZIP/Postal Code
90430-090
Country
Brazil
Facility Name
Hospital Sao Lucas da PUCRS
City
Porto Alegre
State/Province
RS
ZIP/Postal Code
90610-000
Country
Brazil
Facility Name
Hospital Das Clinicas Da Faculdade De Medicina Da Universidade De Sao Paulo Instituto Central
City
Sao Paulo
State/Province
SP
ZIP/Postal Code
05403-900
Country
Brazil
Facility Name
Centro de Pesquisa em Oncologia - CPO
City
Porto Alegre
ZIP/Postal Code
90610-000
Country
Brazil
Facility Name
Instituto Nacional do Cancer
City
Rio De Janeiro
ZIP/Postal Code
RJ 20230 - 130
Country
Brazil
Facility Name
Cross Cancer Institute
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G 1Z2
Country
Canada
Facility Name
Sir Mortimer B. Davis - Jewish General Hospital
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3T 1E2
Country
Canada
Facility Name
Dipartimento di Medicina, Divisione di Oncologia Medica, Istituto Europeo di Oncologia
City
Milano
ZIP/Postal Code
20141
Country
Italy
Facility Name
Divisione di Oncologia
City
Napoli
ZIP/Postal Code
80131
Country
Italy
Facility Name
Uo Oncologia Medica 2 Regione Del Veneto Istituto Oncologico Veneto IRCCS Ospedale Busonera
City
Padova
ZIP/Postal Code
35128
Country
Italy
Facility Name
VU University Medical Center
City
Amsterdam
ZIP/Postal Code
1081 HV
Country
Netherlands
Facility Name
Malmö University Hospital
City
Malmo
ZIP/Postal Code
205 02
Country
Sweden
Facility Name
St Mary's Hospital NHS Trust
City
London
ZIP/Postal Code
W2 1NY
Country
United Kingdom
Facility Name
Imperial College Healthcare NHS Trust - Charing Cross Hospital
City
London
ZIP/Postal Code
W6 8RF
Country
United Kingdom

12. IPD Sharing Statement

Links:
URL
https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4021004&StudyName=Study%20Of%20CP-751%2C871%20In%20Combination%20With%20Exemestane%20In%20Postmenopausal%20Women%20With%20Hormone%20Receptor%20Positive%20Advanced%20Breast%20Cancer
Description
To obtain contact information for a study center near you, click here.

Learn more about this trial

Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

We'll reach out to this number within 24 hrs